Medtronic is touting stellar 7-year postmarketing patient results for one of its key artificial disc implants designed to treat degenerative spinal conditions. Researchers presented the data at a major conference--a shot of good news for the Minnesota company's struggling spinal division.
Medtronic announced Thursday it has approval in the EU and Australia to market its new system for renal denervation to treat uncontrolled hypertension.
Cardiac stents lose out in two new studies that conclude bypass surgery and drugs are better or equal options in helping to prevent future heart attacks from happening, at least for patients with stable heart disease.
St. Jude Medical has begun enrolling patients in a clinical trial to test whether combining peripheral nerve field stimulation and spinal cord stimulation to manage chronic low back and leg pain is more effective than spinal cord stimulation alone.
Seeking to remain ahead of the pack of medical device companies focused on developing neurostimulation devices to treat chronic pain and other conditions, St. Jude Medical has launched a clinical trial of a next-generation device that ups the ante for rivals.
Swiss researchers successfully used a hormone implant to help overweight mice lose weight, an advance that could eventually give gastric bands and other antiobesity devices under development some innovative competition.
Medtronic is touting some positive early data on a stent graft that could expand the patient population for surgery-free endovascular repair, taking advantage of a speedy new FDA pathway set aside for innovative devices.
A massive, 10-year study concluded that stents aren't any better than drugs in treating clogged renal arteries--unwelcome news for stentmakers, as the findings could encourage doctors to rely more on drug treatments first.
A massive study involving next-generation Medtronic devices shows their evolving capacity to do more than just regulate heartbeats; they may also help slow the advance of permanent atrial fibrillation and reduce hospitalization rates, researchers believe.
Fresh off closing a $42 million funding round, CVRx is partnering up with investor DaVita, joining forces to speed up development of the company's nerve-stimulating hypertension treatment.